Abstract: The enzyme serine palmitoyltransferase (SPT) catalyzes the rate-limiting step in the de novo synthesis of sphingolipids. Previously the mammalian SPT was described as a heterodimer composed of two subunits, SPTLC1 and SPTLC2. Recently we identified a novel third SPT subunit (SPTLC3). SPTLC3 shows about 68% identity to SPTLC2 and also includes a pyridoxal phosphate consensus motif. Here we report that the overexpression of SPTLC3 in HEK293 cells leads to the formation of two new sphingoid base metabolites, namely C(16)-sphinganine and C(16)-sphingosine. SPTLC3-expressing cells have higher in vitro SPT activities with lauryl-and myristoyl-CoA than SPTLC2-expressing cells, and SPTLC3 mRNA expression levels correlate closely with the C(16)-sphinganine synthesis rates in various human and murine cell lines. Approximately 15% of the total sphingolipids in human plasma contain a C(16) backbone and are found in the high density and low density but not the very low density lipoprotein fraction. In conclusion, we show that the SPTLC3 subunit generates C(16)-sphingoid bases and that sphingolipids with a C(16) backbone constitute a significant proportion of human plasma sphingolipids. 
The enzyme serine-palmitoyltransferase (SPT) catalyses the rate limiting step in the de-novo synthesis of sphingolipids. Previously the mammalian SPT was described as a heterodimer composed of two subunits -SPTLC1 and SPTLC2. Recently we identified a novel third SPT subunit (SPTLC3). SPTLC3 shows about 68% identity to SPTLC2 and also includes a PLP consensus motif. Here we report that the overexpression of SPTLC3 in HEK293 cells leads to the formation of two new sphingoid base metabolites, namely C 16 -sphinganine and C 16 -sphingosine. SPTLC3 expressing cells have higher in-vitro SPT activities with lauryl-and myristoylCoA than SPTLC2 expressing cells and SPTLC3 mRNA expression levels correlate closely with the C 16 -sphinganine synthesis rates in various human and murine cell lines. Approximately 15% of the total sphingolipids in human plasma contain a C 16 backbone and are found in the high density-and low density-but not the very low density lipoprotein fraction. In conclusion we show that the SPTLC3 subunit is generating C 16-sphingoid bases and that sphingolipids with a C 16 backbone constitute a significant proportion of human plasma sphingolipids.
Introduction:
Sphingolipids comprise a class of bioactive lipids that contribute to plasma membrane and plasma lipoprotein formation and exert a broad range of cellular signaling functions, such as cell proliferation, endocytosis, and the response of cells to inflammatory and apoptotic stress signals (1-4). Sphingolipids are derived from the aliphatic amino alcohol sphingosine which is formed from the precursors L-serine and palmitoyl-CoA. The condensation of serine with palmitoyl-CoA is catalyzed by the enzyme serine-palmitoyltransferase (SPT) [EC 2.3.1.50] and leads to the intermediate 3-ketodihydrosphingosine (3-KDS). 3-KDS is then rapidly converted to dihydrosphingosine (sphinganine) and dihydroceramide. The desaturation of dihydroceramide generates ceramide and the breakdown of ceramide by ceramidase finally forms sphingosine. The sphingosine backbone of ceramide is usually O-linked to a polar head group such as phosphocholine or carbohydrates and amide-linked to an acyl group. The combination of the sphingosine backbone with different head groups, in particular with various oligosaccharides, leads to a complex variety of different sphingolipid metabolites (5, 6) . Moreover, it was shown recently that SPT is also able to use L-alanine as an alternative substrate thereby generating the atypical sphingoid base 1-deoxy-sphinganine (7) . SPT belongs to the family of pyridoxal phosphate (PLP)-dependent α-oxoamine synthases (POAS). Other members of this family include 5-amino-levulinic acid synthase, 2-amino-3 ketobutyrate ligase (KBL) and 8-amino-7-oxononanoate synthase (AONS) (8) . SPT is ubiquitously expressed and enzyme activity has been detected in all tissues tested so far including brain, lung, liver, kidney and muscle (9) . SPT is essential for embryonic development and homozygous SPT knockout mice are not viable (10) . SPT has been believed to be a heterodimer composed of two subunits SPTLC1 and SPTLC2. The two subunits SPTLC1 and SPTLC2 show a similarity at AA level of ~20% and are highly conserved among species. Although both subunits seem to be required for enzyme activity only the SPTLC2 subunit contains a PLP binding motif (8, 11) . Recently, we identified and cloned a novel, third SPT subunit (SPTLC3) (12) . The SPTLC3 sequence shows 68% homology to the SPTLC2 subunit and also includes a PLP consensus motive. The SPTLC3 gene is present in mammals, birds and some lower vertebrates like fish (D. rerio) and frog (X. laevis) but not in invertebrate lineages. The SPTLC3 mRNA has been detected in most human tissues with a particularly high expression in placenta (12) , indicating a special role for SPTLC3 during development and pregnancy. By using immunoprecipitation, native gel analysis, crosslinking studies and size exclusion chromatography it was demonstrated that the native SPT enzyme contains all three subunits and forms a protein complex with a molecular mass of about 460 kDa (13) . However, since SPTLC2 and SPTLC3 are encoded by two distinct genes and expressed within the same cell types we assume a distinct function for the two subunits. One of these differences might be altered substrate affinity or enzymatic activity. This issue is addressed in the present study.
Experimental procedures
Cell lines HEK293 cells were obtained from ATCC and cultured in full medium (DMEM, Sigma) containing 10% fetal bovine serum (Fischer scientific) and Penicillin/Streptomycin (100 units per ml/0.1mg per ml). HEK293 cells were transfected with lipofectamine 2000 (Invitrogen) and selected for neomycine resistance (G418, 400μg/ml) to generate a pool of stably expressing cells. The expression of each of the SPT subunits in the three cell lines was confirmed by western blots. Fumonisin B1 dependent accumulation of sphingoid bases Fumonisin B1 (Sigma) was added to the media of exponentially growing cells at a final concentration of 10µg/ml. As a negative control myriocin (10µg/ml, Sigma) was added together with Fumonisin B1. 24h after Fumonisin B1 addition, cells were washed twice with PBS, harvested and counted (coulter® Z2, Beckman Coulter). Synthetic C17 sphingosine (Avanti Polar Lipids) was added to each sample as an internal extraction standard. SPT activity assay Cells were grown in 10 cm dishes to approximately 80% confluency. Medium was removed and the cells were washed two times with PBS and harvested in 1ml of PBS by scraping. The suspension was transferred into a 1.5 ml reaction tube. Cells were pelleted by centrifugation (2500 g, 2 min at 4°C) and resolved in assay buffer (50 mM Hepes pH 8.0, 0.5 mM MnCl 2 ). The protein concentration was adjusted to 2 mg/ml. Protein concentrations of the cell lysates were determined using the Bradford Assay (BioRad). Albumin was used as calibration standard. The reaction cocktail for measuring invitro SPT activity was composed of 400 µg total lysate protein, 50 mM Hepes (pH The assay was performed at 37°C for 60 min. For the negative controls SPT activity was specifically blocked by the addition of the SPT inhibitor myriocin (40 µM, Sigma). The reaction was stopped by adding 0.5 ml methanolic-KOH:CHCl 3 (4:1) to the mixture. Methanolic KOH was prepared by dissolving 0.7 g KOH pellets in 100 ml MeOH. Lipids were extracted at 37°C under steady agitation for 30 min. Subsequently 500 µl CHCl 3 , 500 µl alkaline water (100 µl NH 4 (2 N) in 100 ml H 2 O) and 100 µl NH 4 (2 N) was added in this order. Phases were separated by centrifugation (13000 g, 5 min) and the upper phase discarded. The lower phase was washed three times with alkaline water. Finally the lower organic phase was transferred to a scintillation vial and the CHCl 3 evaporated under a stream of N 2 . After the addition of scintillation cocktail the radioactivity was quantified on a Scintillation Analyzer (Packard Liquid 1900TR). Quantitative RT-PCR The mRNA was extracted using Tri Reagent (Molecular Research Center, Inc., Cincinnati, US) and transcribed to cDNA using oligo dT primers and Superscript III (Invitrogen) according to manufacturer's instructions. Specific primers for the different SPT subunits were designed using the Oligo6.0 software (Molecular Biology Insights, Cascade, USA). Light Cycler PCR was performed using the DNA Master Kit (Roche Diagnostics, Rotkreuz, Switzerland) according to the manufacturer's instructions. The following primer pairs were used (0.4 µM each): huSPTLC3fw:
5`-TGCAGCCAAGTATGATGAGTCTA -3`; huSPTLC3rv:
5`-GCAGATGCACGATGGAAC -3` moSPTLC3fw:
5`-GGCTTGCAGGGAAATATG-3`; huSPTLC3rv:
5`-GGATGACTGAAGTGTGGTTA-3` Amplification was carried out for SPTLC3: 50 cycles, each consisting of 10 s at 95 °C; 10 s at 61°C; 20 s at 72°C. The linearity of the assays was determined by serial dilutions of the templates for each primer set separately. Separation of plasma lipoproteins Plasma was isolated from healthy normolipidemic donors after overnight fasting. Three ml plasma was fractionated on a four step density gradient essentially as described (14) . Ultracentrifugation was performed in a Beckman SW-40 swinging bucket rotor for 24 h at 41000 rpm at 15°C. Fractions (1 ml) were collected from the top of the centrifuge tube and analyzed for triglyceride, cholesterol and other lipids.
Lipid extraction and hydrolysis
Total lipids were extracted and, prior to analysis, either base or acid/ base hydrolyzed (15) . Briefly, cells were resuspended in 200 µl PBS and lipids extracted in 1 ml extraction buffer (2 vol. methanol/1 vol. chloroform + 0.15 µl/ml C17 SO (1mM in EtOH). 100 µl of NH 4 (2 N) was added and the lipids were extracted under constant agitation (1 h, 37°C). Subsequently 0.5 ml chloroform was added and samples were centrifuged (12000 g, 5 min) to separate the organic from the water phase. The upper (water) phase was discarded and the lower phase washed twice with 1 ml of alkaline water (1 ml NH 4 (2 N) in 100 ml water) and dried under N 2 . For acid hydrolysis, the dried lipids were resupended in 200 µl methanolic HCl (1 N HCl/10 M water in methanol) and kept at 65°C for 12-15 hours. The solution was neutralized by the addition of 40 µl KOH (5 M) and subsequently subjected to as follows: 0.5 ml extraction buffer (4 vol. 0.125 M KOH in methanol + 1 vol. chloroform) was added and mixed. Subsequently, 0.5 ml chloroform, 0.5 ml alkaline water and 100 µl NH 4 (2 N) was added in this order. Liquid phases were separated by centrifugation (12000 g, 5 min). The upper phase was aspirated and the lower phase washed twice with alkaline water. Finally, the lipids were dried by evaporation of the chloroform phase under N 2 and subjected to LC-MS analysis. Plasma lipids were analyzed from 100 µl of human EDTA-treated plasma which was treated in the same manner.
LC-MS
Extracted lipids were solubilized in 56.7% methanol/33.3% ethanol/10% water and derivatized with ortho-phthaldialdehyde (OPA, Sigma) (15) . The lipids were separated on a C 18 column (Uptispere 120Å, 5µm, 125x2mm, Interchim, France) and analyzed by a serial arrangement of a fluorescence detector (HP1046A, Hewlett Packard) followed by a MS detector (LCMS-2010A, Shimadzu). APCI (atmospheric pressure chemical ionisation) was used for ionisation. Non natural C17 sphingosine (Avanti Polar Lipids) was used as the internal standard.
Results

SPTLC3 expressing cells generate C 16 sphingoid bases
The human SPT subunits SPTLC1, SPTLC2 and SPTLC3 were cloned into a pcDNA3.1 expression vector and expressed in HEK293 cells as reported earlier (12) . HEK293 cells were chosen since they express low endogenous levels of SPTLC3 mRNA (Fig.4A ). All subunits were expressed at comparable levels as demonstrated by western blot analysis and showed no signs of degradation (12) . To determine if SPTLC3 expressing cells generated more, or other, sphingoid bases we compared the spectrum of de novosynthesized sphingoid bases between SPTLC3 deficient (HEK Cnt ) and SPTLC3 overexpressing cells (HEK SPTLC3 ). This was done by blocking the de novo synthesis pathway at the step of the ceramide synthase (CerS) with Fumonisin B1 (FB1). The inhibition of CerS leads to a time dependent accumulation of its substrate sphinganine (SA). Hence, potential side products of the SPT reaction are also accumulating under these conditions (7) . The accumulated lipids were extracted 24h after the addition of FB1, derivatized with orthophtaldialdehyde (OPA) and analyzed on a C18 reverse phase column with a serially arranged fluorescence and MS detector (15) .
In the presence of FB1 we observed a significant accumulation of sphinganine ( Fig.1A) whereas no SA accumulation was seen when SPT activity was blocked with myriocin. In parallel we observed the appearance of a second unknown peak which eluted prior to SA after 8.2 min. Because of similar retention times this peak was partly overlaid by the internal standard (C 17 -SO) which was added for normalization. (Fig.1B) . Accumulation of SA but also of this unknown peak was not observed when SPT activity was inhibited with myriocin. This observation indicates that the unknown metabolite is a product of the SPT reaction. Subsequent MS analysis revealed that the unidentified metabolite had an m/z of 450.3 (as an OPA derivate). 
SPTLC3 has higher activity with C 12 and C 14 acyl-Co-A
To test this hypothesis we compared the invitro SPT activity with various acyl-CoA substrates in extracts from control, SPTLC1-, SPTLC2-and SPTLC3-overexpressing cells. All acyl-CoAs were used at the same concentration (50 µM). In comparison the SPTLC3 expressing cells showed a significantly higher activity with lauryl-CoA and myristoyl-CoA than did the control, SPTLC1-or SPTLC2-expressing cells ( Fig.2A) . This suggests that the SPTLC3-mediated SPT activity is primarily responsible for the generation of sphingoid bases with a C 14 or C 16 backbone whereas the SPTLC2 subunit seems to be more specific for longer acyl-CoAs thereby forming C 18 and C 20 -sphingoid bases.
C 16 -SA generation is stimulated by serine
The addition of L-serine to the cell culture medium generally stimulates SPT activity and SA de-novo synthesis (7). To determine if L-serine also stimulated SPTLC3 mediated C 16 -SA generation, we compared the accumulation of C 16 
Kinetic analysis of SPTLC3 activity
To obtain further insight into the enzymatic mechanism we compared the kinetics for myristoyl-CoA and palmitoylCoA in HEK Cnt and HEK SPTLC3 cells. For palmitoyl-CoA the enzyme followed a Michaelis-Menten kinetics up to a concentration of about 0.1 mM (Fig. 3A) . The kinetics with palmitoyl-CoA was essentially the same in HEK Cnt and HEK SPTLC3 cells. At palmitoyl-CoA concentrations above 0.15 mM substrate inhibition was observed in accordance to earlier reports (16, 17) . Also the HanesWoolf plot (18) showed a linear relationship between [S] and 1/v up to a palmitoyl-CoA concentration of 0.1mM (Fig. 3A) . For myristoyl-CoA we observed an about 5-fold higher activity in HEK SPTLC3 cells compared to HEK Cnt cells (Fig. 3B) . As for palmitoyl-CoA we also observed an inhibitory effect of myristoylCoA at higher concentrations. For both substrates the optimal activity was in a concentration range of 0.1-0.125 mM. Km and Vmax values (Fig. 3C) cells were comparable whereas the maximal velocity for myristoyl-CoA was about 50% lower than for palmitoyl-CoA (Fig. 3C ).
SPTLC3 mRNA levels correlate with C 16 -SA accumulation in FB1 blocked cells
To further confirm that the generation of C 16 -SA is linked to the expression of SPTLC3, we analysed the SPTLC3 mRNA levels in various human and non-human cell lines (Fig.4A) . Some cell lines like HEK293 or the human monocytic cell line THP1, showed very low SPTLC3 mRNA expression whereas intermediate levels were found in HepG2, COS and NIH/3T3 cells. The highest SPTLC3 mRNA levels were in the trophoblast lines JAR and JEG-3 as reported earlier (12) . The SPTLC3 mRNA levels showed a close correlation with the levels of accumulated C 16 -SA in these cells (Fig. 3B) , providing further evidence that C 16 -sphingoid bases are primarily generated by SPTLC3.
C 16 -SA is metabolized to C 16 -SO
The observation that C 16 -SA accumulates in the presence of the CerS inhibitor FB1 indicates that C 16 -SA is also a substrate for CerS. Consequently, the generated C 16 -SA is further metabolized to C 16 -dihydroceramide and to C 16 -ceramide. The degradation of C 16 -ceramide by ceramidase would finally lead to the generation of C 16 sphingosine (C 16 -SO). To test whether the SPTLC3-expressing cells also produce C 16 -SO we compared the total sphingoid base content between HEK Cnt and HEK SPTLC3 cells. In view of the great variety of fatty acids and possible head groups that can be attached to the sphingoid backbone, a complete analysis of all possible C 16 -ceramide variants is a demanding task and will be addressed in future studies. To simplify the analysis we, therefore, subjected the extracted lipids to acid and base hydrolysis. Under acidic conditions the amide bond of the conjugated fatty acid is released whereas the O-linked phosphoester and carbohydrate moieties of the sphingoid base head group are removed under basic conditions. This procedure allowed the quantification of the total C 16 and C 18 sphingoid base levels in the cells. The molecular mass of SO and SA differs, due to the Δ4 double bond, by two Daltons. As described above we observed a significant FB1 dependent accumulation of C 16 . 6 ). To further demonstrate that the identified metabolite is C 16 -SO we compared its retention time with respect to other sphingoid bases with different carbon chains. On a C 18 reverse phase column sphingoid bases show a logarithmic correlation between retention time and their carbon chain length (Fig. 5B) . Regression analysis of this function revealed a theoretical retention time for C 16 -SO of 6.5 min which is in agreement with the observed retention time (6.45 min) of the identified metabolite (Fig. 3A,B) . Our studies also show that the C16-SO levels of acid/base treaded cell lines closely correlate with C16-SA which can be assumed to be the metabolic precursor (Fig. 5C ).
Up to 15% of human plasma sphingolipids are based on a C 16 -backbone
The observation that SPTLC3 is responsible for the generation of C 16 sphingoid bases raised the questions of whether these lipids are also present in human plasma and how they are transported in plasma. We analyzed plasma samples of 20 healthy donors. The plasma was acid/base treated and analyzed by LC-MS. The analysis showed that the majority of plasma sphingolipids are based on a C 18 sphingosine backbone. Nevertheless, an astonishingly high fraction of plasma sphingolipids was found with a C 16 -SO backbone (Fig. 6A) . The proportion of C 16 -SO in total plasma SO may be as high as 15%. The fraction of plasma sphingolipids which contained a SA backbone was much lower. About 4% of the plasma sphingolipids contained a sphingosine backbone whereas 15-20% of the total SA contained a C 16 -backbone. The analysis of lipoprotein fractions which were isolated by ultracetrifugation demonstrated that both, the C 16 -and the C 18 -sphingolipids are present in the LDL and HDL fractions but not in the VLDL fraction (Fig. 6B) . In comparison to total cholesterol and triglyceride the sphingolipids showed a shoulder in fractions 9 and 10 indicating that they are also part of a denser HDL subfraction.
Discussion
The fact that SPTLC2 and SPTLC3 both form a catalytically active SPT holoenzyme raises questions about the functional differences between these two isoforms. Here we report that the presence of SPTLC3 enables the enzyme to metabolize shorter acyl-CoAs, like lauroyland myristoyl-CoA in contrast to the predominant usage of palmitoyl-CoA by SPT in the absence of SPTLC3. In HEK293 cells, which endogenously express insignificant levels of this subunit only, we observed the appearance of two novel sphingolipid metabolites in cells overepxressing SPTLC3. The two novel metabolites were identified as C 16 cells showed that SPTLC1 and SPTLC2 mRNA levels do not change upon SPTLC3 expression (data not shown), implying that the SPTLC3 subunit has a rather specific affinity for myristoylCoA and only a minor affinity for palmitoyl-CoA.
Otherwise the overexpression of SPTLC3 would have influenced the Vmax for palmitoyl-CoA as well. These findings suggest that SPTLC3 is predominantly responsible for the generation of C 14 and C 16 -sphingoid bases, making SPTLC3 functionally distinct from the SPTLC2 subunit. Previously, Merrill and co-workers analyzed SPT activities with different fatty acid-CoA thioesters in microsomes of various rat tissues (9) . Some of the tested tissues showed higher activities with shorter alkyl chains than others. This observation might be explained by different SPTLC3 expression levels in these tissues. The identification of three SPT subunits two of which contain a binding site for the PLP cofactor, raises further questions about the structure of the SPT holoenzyme. In analogy to other members of the POAS family it has been assumed that the active SPT is a heterodimer. However, size exclusion chromatography and crosslinking data indicate that the SPT is a holoenzyme and simultaneously composed of all three subunits (13). It is not clear yet whether all three subunits are required to form an active SPT enzyme. The fact that some cells, like HEK293, express only minor levels of this subunit indicate that SPTLC3 is not essential for forming an active enzyme. Nevertheless, the size exclusion chromatography data revealed a molecular mass of 460 kDa for the active SPT complex -independent of the presence or absence of SPTLC3 (13) . This might be explained by a dynamic stoichiometry of the complex in which the SPTLC2 and SPTLC3 subunits can substitute for each other. A second possibility would be an association with further yet unidentified proteins. In this context it is interesting that, very recently, a fourth SPT subunit was reported (20) . Han et al. identified two short polypeptides which interact with SPTLC1 and SPTLC2. The expression of these two proteins stimulated SPT activity and modulated the substrate preference of SPT towards the use of longer acyl-CoA (20) , indicating a regulatory function for these polypeptides. However, it is currently not clear how these new proteins can be integrated into the concept of SPT structure and function.
Besides C 16 -SA, we also observed the presence of C 16 -SO in acid/base treated lipid extracts of SPTLC3-expressing cells. Since a C 16 -SO standard is commercially not available the identification of this metabolite is based on several indirect pieces of evidence. The conformity of the identified C 16 -SO is based on its mass (Fig.  5A) , the retention time (Fig. 5B ) and the correlation with its precursor C16-SA (Fig.  5C) . We also confirmed the presence of this metabolite in lipid extracts from Drosophila (data not shown); insects have been reported to generate primarily C 16 -sphingoid bases (21). Thus, it appears that C 16 -SA can be further metabolized to C 16 -dihydro-ceramide/C 16 -ceramide and finally also degraded to C 16 -SO. This indicates that potentially all types of sphingolipids, including glyco-and phosphosphingolipid, could be formed on the basis of a C 16 sphingosine backbone. These findings greatly expand the already huge variety of possible sphingolipid variants and might also influence the understanding of these lipids. In comparison to C 18 sphingoid bases sphingoid bases with a C 16 backbone are considerably less hydrophobic and hence likely exhibit significant differences in biophysical properties. The C 16 -sphingolipids will exchange much more rapidly with a hydrophilic environment which might influence their subcellular localization and their distribution in membranes which, in turn, may have important implications for transport and translocation as well as cellular signal transduction. Curiously there are only few reports on C 16 -sphingolipids in the literature. Sphingoid bases with a C 14 and C 16 carbon chain are the predominant sphingolipids in insects (21, 22) . Recent studies of a marine virus (Coccolithovirus) revealed that the viral genome contains a cluster of putative sphingolipid biosynthetic genes, including an SPT-like enzyme (23) that utilizes myristoyl-CoA and therefore generates C 16 sphingoid bases when expressed in yeast. Sphingoid bases with 16 carbon atoms were also found in bovine milk (24, 25) and as a part of the black epidermis from the antarctic minke whale (26) . A few earlier reports indicate the presence of C 16 sphingoid bases in human plasma (27,28). Interestingly, certain human tissues like placenta show pronounced expression of SPTLC3 (12) and contain high levels of C 16 sphingoid bases (data not shown). This was also seen in human trophoblast cell lines like JEG-3 and JAR in which high SPTLC3 mRNA expression correlated with high C 16 sphingoid base levels (Fig.  4B) . The unusually high level of SPTLC3 mRNA in placental tissue suggests a specific physiological role for these metabolites during embryogenesis and pregnancy. Also, the finding that approximately 15% of human plasma sphingolipids contain a C 16 backbone indicates a significant physiological relevance of these metabolites. The source of the C 16 sphingolipids in plasma is not yet known but we have demonstrated that plasma C 16 -and C 18 -sphingoid bases are transported in HDL and LDL but not in the VLDL lipoproteins fraction (Fig. 6B) indicating that C 16 -sphingoid bases are at least partly metabolized by the liver. In this respect it is interesting that elevated plasma sphingolipid levels are associated with an increased risk of developing atherosclerosis and coronary heart disease (29, 30) . Myriocin lowered plasma sphingolipids in ApoE knock-out mice and significantly reduced the formation of atherosclerotic lesions in these mice and showed a significant delay of disease progression (31-33). Since treatment with myriocin would be expected to lower the levels of both C 16 -and C 18 -based sphingolipids it would be interesting to determine if one of the two subclasses is primarily involved in the pathogenesis of atherosclerosis. In this context, analysis of the C 16 -sphingoid bases in plasma of 15 wild-type mice (C57BL/6) showed significantly lower levels (about 90% less) of C 16 sphingoid bases in mice although the levels of the C 18 sphingoid bases were comparable (data not shown). Low levels of C 16 -sphingoid bases were also seen in rat plasma (data not shown). On the other hand, rodent and human cell lines showed similar SPTLC3 activities when normalized to mRNA expression (Fig. 4B) , indicating that the lower C 16 -SO levels in mouse plasma are due to a different C 16 -SO metabolism and not simply caused by a lower SPTLC3 activity in mice. It should therefore be considered that rodents and humans are distinct with respect to C 16 -sphingolipid metabolism, a fact that should be kept in mind when working with rodent models of disease. In conclusion, the observation that SPTLC3 is found in all higher vertebrates and that its presence is primarily linked to the generation of C 16 sphingoid bases, indicate an evolutionarily conserved need for these types of sphingolipids. However, the distribution, metabolic fate and biochemical properties of these lipids have to be addressed in future studies. 
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